Ultimovacs
@ultimovacs
Followers
635
Following
564
Media
53
Statuses
580
Clinical-stage IO biotech on a mission to extend and improve the lives of patients. Follow us here: https://t.co/xWypAtTlLC
Norway & Sweden
Joined September 2020
We are no longer active on Twitter/X. For company updates and news, please follow us on LinkedIn: https://t.co/hQmqmqc1N0
3
0
1
Ultimovacs — Peer-reviewed publication reiterates UV1’s potential. $ULTI #OSE @ultimovacs
https://t.co/sPuIzOY639
edisongroup.com
Ultimovacs’ results from the Phase II NIPU trial for its universal, off-the-shelf cancer vaccine UV1 in second-line metastatic pleural mesothelioma (MPM) have been published in the European Journal...
5
1
8
Ultimovacs is a #biotech company developing novel immunotherapies against cancer. Watch executive interview with Jens Bjørheim, CMO of Ultimovacs, who discusses the company’s key asset, UV1, and upcoming milestones/catalyst: https://t.co/70mqWWGozX
@ultimovacs $ULTI #OSE
edisongroup.com
In this video, Soo Romanoff, healthcare managing director of Edison Group, interviews Jens Bjørheim, CMO of Ultimovacs, who discusses the company’s key asset, UV1, and upcoming milestones/catalysts...
4
2
13
Congrats to the NIPU investigator team with publication in European Journal of Cancer! #mesothelioma #phase2
Survival-data from the NIPU-trial randomising pts with pleural mesotheliom to double ICI alone or with telomerase vaccine UV1.
2
2
21
0
0
12
A positive opinion from @EMA_News for @ultimovacs #uv1 #mesothelioma vaccine combination #therapy, shortly after ftd from @US_FDA
#vaccinenation #vaccines #vaccine #cancer #cancerresearch #therapeutic #ultimovacs
https://t.co/B8jdsYUclC
vaccinenation.org
Ultimovacs announced in February 2024 that the European Medicines Agency (EMA) has issued a “positive opinion” on its application for Orphan
0
2
6
UV1 Receives Orphan Drug Designation From EMA in Mesothelioma https://t.co/PlwbzlDsjX via @onclive
onclive.com
The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.
0
1
20
Excited to start the week with more good news: Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of #Mesothelioma from @EMA_News #immunotherapy
https://t.co/SYZVFyY3Tc
0
1
19
Our CEO Carlos de Sousa was at @Finansavisen TV today - watch the interview here: https://t.co/SVp2erZgYy?
#immunotherapy #CancerResearch
0
1
12
Read about the randomized Ph2 FOCUS trial in head and neck cancer, expected readout H2 2024: https://t.co/VMYGnXp2Wm
#cancerresearch #immunotherapy #cancervaccine
frontiersin.org
Background: Globally, head and neck squamous cell carcinoma (HNSCC) is the seventh most common malignancy. Despite aggressive multimodal treatment approaches...
0
2
12
FDA Fast Tracks Ultimovacs' Novel Cancer Vaccine for Malignant Pleural Mesothelioma https://t.co/Ud26WgvXSl via @PharmExec
pharmexec.com
UV1 plus ipilimumab (Yervoy) and nivolumab (Opdivo) produced a statistically significant and clinically meaningful survival improvement in patients with unresectable malignant pleural mesothelioma.
0
0
8
Ultimovacs Receives FDA #FastTrack Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable #Mesothelioma #biotech #immunotherapy #Phase2
https://t.co/OKMYH6cXJM
0
9
39
Read the interview with @EllingsenEspen in @DrugTargetRev - Immuno-oncology innovations redefining cancer treatment in 2024 #CancerResearch #immunotherapy #biotech
drugtargetreview.com
Dr Espen Basmo Ellingsen provides insights into the personalised strategies that elevate the effectiveness of immuno-oncology interventions.
0
2
11
Resultater fra Ultimovacs-studie er snart klare: Topplinjedataene fra føflekkreftstudien til Ultimovacs kommer i mars.
medwatch.no
Topplinjedataene fra føflekkreftstudien til Ultimovacs kommer i mars.
0
2
17
Updated Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant #Melanoma: Topline Results expected in March 2024 ⏳ https://t.co/kF0xhhijxc
1
2
14